Results 241 to 250 of about 101,617 (297)

Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention. [PDF]

Cancers (Basel)
Laeeq T, Ahmed M, Sattar H, Zeeshan MH, Ali MB.   +4 more
europepmc   +1 more source

Prevalence and Predictors of Adverse Events Associated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetic Patients: A Cross-sectional Study. [PDF]

Clin Med Insights Endocrinol Diabetes
Reghunath SR, Chackochan A, Thunga G, Acharya DU, Shivashankara KN, Ravindra Prabhu A, Acharya LD.   +6 more
europepmc   +1 more source

RETRACTED: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis.

PLoS One
Hasan R, Chugaeva UY, Mohammadian M, Zamanifard S, Mohammadian-Hafshejani A.   +4 more
europepmc   +1 more source

Erratum: Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis [Corrigendum]. [PDF]

Diabetes Metab Syndr Obes
europepmc   +1 more source

DPP-4 Inhibitors in Clinical Practice [PDF]

Postgraduate Medicine, 2009
Type 2 diabetes is a very common worldwide disorder, with major consequences for patients, society, and health care services. Good glycemic control is an important aspect of diabetes management because it has a significant impact on diabetes-related microvascular and possibly macrovascular complications.
Palalau, Anna I., Tahrani, Abd A., Piya, Milan K. (R19111), Barnett, Anthony   +3 more
openaire   +4 more sources

DPP-4 inhibitors [PDF]

Insulin, 2007
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion, thereby lowering glucose levels.
Ahrén, Bo
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Pharmacoeconomic analysis of DPP-4 inhibitors

Die Pharmazie, 2013
Dipeptidyl peptidase-4 (DPP-4) inhibitors and other incretin-related drugs have attracted attention as antidiabetic agents, but they are expensive. The Japanese government has adopted a policy of reducing healthcare costs, and medical institutions must provide medical care while considering economic efficiency.
H, Teramachi, H, Ohta, T, Tachi, M, Toyoshima, T, Mizui, C, Goto, T, Tsuchiya   +6 more
openaire   +3 more sources

The Research Progress of DPP-4 Inhibitors

Mini-Reviews in Medicinal Chemistry, 2020
Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients.
Zhi-Gang, Sun, Zhi-Na, Li, Hai-Liang, Zhu   +2 more
openaire   +2 more sources